Introducing ▼ REZZAYO® (rezafungin) the first once weekly echinocandin indicated for the treatment of invasive candidiasis in adults.
Introducing ▼REZZAYO® (rezafungin) the first once weekly echinocandin indicated for the treatment of invasive candidiasis in adults.
Get access to exclusive content and news updates:
27:15 
English 
Professor Tihana Bicanic
Reader and Consultant in Infectious diseases at St George's University of London.
Professor Oliver Cornely
Director & Chair of Translational Research at the CECAD Institute of the University of Cologne, and Scientific Director of the Center for Clinical Trials. Clinically, he serves as Infectious Diseases Consultant at the University Hospital of Cologne, Germany.
Professor Matteo Bassetti
Head of the Infectious Diseases Clinic of the Policlinico San Martino University Hospital in Genoa and Professor of Infectious Diseases of the University of Genoa, Italy.
Related Webinars
▼REZZAYO® Patient Case Study - Pharmacist Ahmad Simreekheea
▼REZZAYO® (rezafungin) Patient Case Study - Pharmacist Ahmad Simreekheea
Ahmad Simreekheea
Watch as Ahmad Simreekheea discusses his experience with using REZZAYO(R) in a patient case study.
Ahmad Simreekheea
Antimicrobial Pharmacist, MSc
Video descripton: Watch as Ahmad Simreekheea discusses his experience with using REZZAYO® in a patient case study.
Implementation of ▼REZZAYO® Rezafungin through formulary submission
Implementation of ▼REZZAYO® Rezafungin through formulary submission
Stephen Hughes
Implementation of REZZAYO® through formulary submission
Stephen Hughes
Antimicrobial Pharmacist MPharm, MSc, MBA
Watch as Consultant Antimicrobial Pharmacist Stephen Hughes talks about REZZAYO® and his experience with submitting for formulary at the Chelsea & Westminster NHS Trust.